ABVC BioPharma (NASDAQ:ABVC) Issues Earnings Results

ABVC BioPharma (NASDAQ:ABVC) issued its earnings results on Tuesday. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.36, FiscalAI reports.

ABVC BioPharma Stock Up 0.5%

Shares of ABVC stock traded up $0.01 during mid-day trading on Wednesday, reaching $0.99. 2,261 shares of the stock traded hands, compared to its average volume of 100,058. The stock’s fifty day simple moving average is $1.02 and its two-hundred day simple moving average is $1.23. ABVC BioPharma has a 1-year low of $0.71 and a 1-year high of $3.06. The company has a market cap of $26.56 million, a price-to-earnings ratio of -3.32 and a beta of 0.47.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ABVC BioPharma in a report on Friday, September 11th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.

About ABVC BioPharma

ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and oncology-related conditions, as well as certain medical devices. The company advances product candidates through preclinical and clinical development and works with research, development and commercialization partners. ABVC’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions, along with oncology programs targeting cancer treatment.